- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02542020
Prospective Evaluation of HIV Patients Using Non-invasive Methods for Estimation of Liver Fibrosis and Steatosis (Prospec-HIV)
Prospective Evaluation of HIV Infected Patients Followed at Evandro Chagas National Institute of Infectious Disease (INI) - Oswaldo Cruz Foundation (FIOCRUZ) Using Non-invasive Methods for Estimation of Liver Fibrosis and Steatosis
Human immunodeficiency virus (HIV) infection is a major global health issue with up to 40 million people infected worldwide. Due to highly active antiretroviral therapy, mortality related to acquired immunodeficiency syndrome (AIDS) has been reducing in the last decades. However, liver disease remains as an important cause of severe complications and death.
Hepatic fibrosis progression is the main responsible for liver-related outcomes in HIV-positive patients. Co-infection by hepatitis B (HBV) or hepatitis C virus (HCV) is highly prevalence in HIV patients. Chronic viral co-infection induces faster liver fibrosis progression compared to mono-infected HIV. However, published data have been reporting presence of significant liver fibrosis in HIV without HBV or HCV infection. This might be related to direct action of HIV in hepatocytes or association with others factors, such as non-alcoholic fatty liver disease (NAFLD). NAFLD is associated with metabolic factors, such as obesity and type-2 diabetes mellitus. However, antiretroviral drugs may induce abnormal body fat distribution (lipodistrophy) and insulin resistance playing an important role on this process. Liver biopsy has been historically considered as the gold standard to evaluate liver injury. However, this painful method presents several limitations. Therefore, several non-invasive methods for estimation of liver fibrosis, such as biomarkers (APRI, FIB-4, FibroTest and FibroMeter) and transient elastography by Fibroscan, have been developed as an alternative to liver biopsy. The diagnostic performance and prognostic value of biomarkers and transient elastography have been validated in patients with chronic liver diseases. However, few data are available in HIV patients, especially in those without chronic viral co-infection.
Therefore, patients, medical doctors and scientific community will be beneficiated by the future application of non-invasive methods for estimation of liver injury in clinical practice in HIV patients.
Descripción general del estudio
Estado
Descripción detallada
In HIV-positive patients with or without chronic viral hepatitis co-infection, the primary aims of this project are: (i) to estimate the prevalence and incidence of liver injury (including progression of fibrosis, necro-inflammatory activity and steatosis) and to report the normal values of non-invasive methods in HIV population; (ii) to validate the diagnostic performance of non-invasive methods using a method without a gold standard (Latent Class Analysis); (iii) to validate the prognostic value of non-invasive markers to predict overall mortality and liver-related outcomes and (iv) to correlate liver injury with nutritional status. The secondary aim will be the constitution of a cohort of HIV patients, with or without chronic viral hepatitis co-infection for long-term follow-up of severe outcomes.
This prospective cohort study has been approved by the Local Ethical Committee (CAAE: 32889514.4.0000.5262) and it has been enrolling patients from June 2015 at the Evandro Chagas National Institute of Infectious Diseases - Oswaldo Cruz Foundation (INI - FioCruz), Rio de Janeiro, Brazil. A total of 2,000 patients will be included in this study during the next 5 years. This project aims to report the prevalence and incidence of liver disease in a representative sample of HIV patients with and without chronic viral hepatitis co-infection. In addition, the risk factors associated to presence and progression of liver fibrosis and steatosis will be identified and an innovative non-invasive management for estimation of liver injury in HIV patients will be validated.
Patients have been submitted at the same day to the following procedures: (i) clinical examination (anthropometric and demographic characteristics), (ii) blood sample collection (for blood analysis, calculation of biomarkers and stockage of samples), (iii) transient elastography (with M and XL probes by a single experienced operator (>2,000 examinations) and (iv) nutritional status (bioelectrical impedance and 24h diet recall).
Tipo de estudio
Inscripción (Anticipado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Rio De Janeiro/RJ
-
Rio de Janeiro, Rio De Janeiro/RJ, Brasil, 21040-360
- Reclutamiento
- Evandro Chagas National Institute of Infectious Diseases
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- HIV infection
- Age >= 18 years
Exclusion Criteria:
- Auto-immune hepatitis
- Primary biliary cirrhosis
- Primary sclerosing cirrhosis
- Extra-hepatic cholestasis
- Acute viral hepatitis
- Hepatic ischemia
- Hepatic metastasis
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Grupo
- Perspectivas temporales: Futuro
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Evaluation of stage of fibrosis and grade of steatosis in patients infected by HIV
Periodo de tiempo: change of fibrosis stage and steatosis grade from baseline at 5 years
|
Staging of liver fibrosis and quantification of steatosis using non-invasive methods and correlation with risk factors
|
change of fibrosis stage and steatosis grade from baseline at 5 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Prognostic value of non-invasive methods
Periodo de tiempo: up to 5 years
|
Evaluation of the prognostic value of non-invasive methods for prediction of severe outcomes and mortality
|
up to 5 years
|
|
Prevalence of liver fibrosis
Periodo de tiempo: up to 3 years
|
Estimation of liver fibrosis by non-invasive methods
|
up to 3 years
|
|
Prevalence of liver steatosis
Periodo de tiempo: up to 3 years
|
Estimation of liver steatosis by non-invasive methods
|
up to 3 years
|
|
Diagnostic performance of non-invasive methods
Periodo de tiempo: up to 3 years
|
Evaluation of diagnostic accuracy (sensitivity and specificity) of non-invasive methods using the Latent Class Analysis
|
up to 3 years
|
|
Nutritional status
Periodo de tiempo: From date of inclusion until the date of first documented alteration on nutritional status, assessed up to 5 years
|
Evaluation of the nutritional status by bioelectrical impedance and 24h diet recall
|
From date of inclusion until the date of first documented alteration on nutritional status, assessed up to 5 years
|
|
Progression of liver fibrosis
Periodo de tiempo: From date of inclusion until the date of first documented progression of liver fibrosis, assessed up to 5 years
|
Estimation of liver fibrosis by non-invasive methods
|
From date of inclusion until the date of first documented progression of liver fibrosis, assessed up to 5 years
|
|
Progression of liver steatosis
Periodo de tiempo: From date of inclusion until the date of first documented progression of liver steatosis, assessed up to 5 years
|
Estimation of liver steatosis by non-invasive methods
|
From date of inclusion until the date of first documented progression of liver steatosis, assessed up to 5 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Valdilea G Veloso, PhD, Oswaldo Cruz Foundation
- Investigador principal: Beatriz Grinsztejn, PhD, Oswaldo Cruz Foundation
Publicaciones y enlaces útiles
Publicaciones Generales
- Yanavich C, Perazzo H, Li F, Tobin N, Lee D, Zabih S, Morata M, Almeida C, Veloso VG, Grinsztejn B, Aldrovandi GM. A pilot study of microbial signatures of liver disease in those with HIV mono-infection in Rio de Janeiro, Brazil. AIDS. 2022 Jan 1;36(1):49-58. doi: 10.1097/QAD.0000000000003084.
- Yanavich C, Pacheco AG, Cardoso SW, Nunes EP, Chaves U, Freitas G, Santos R, Morata M, Veloso VG, Grinsztejn B, Perazzo H. Diagnostic value of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV. HIV Med. 2021 Jul;22(6):445-456. doi: 10.1111/hiv.13060. Epub 2021 Feb 2.
- Perazzo H, Cardoso SW, Yanavich C, Nunes EP, Morata M, Gorni N, da Silva PS, Cardoso C, Almeida C, Luz P, Veloso VG, Grinsztejn B. Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy. J Int AIDS Soc. 2018 Nov;21(11):e25201. doi: 10.1002/jia2.25201.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Procesos Patológicos
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Enfermedades del sistema inmunológico
- Enfermedades de virus lentos
- Enfermedades del HIGADO
- Fibrosis
- Infecciones por VIH
- Cirrosis hepática
- Síndrome de inmunodeficiencia adquirida
- Síndromes de deficiencia inmunológica
Otros números de identificación del estudio
- 32889514.4.0000.5262
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .